Lupus & antiphospholipid syndrome
Calprotectin Impairs Platelet Survival in Patients With Primary Antiphospholipid Syndrome
Authors' conclusion
These data suggest that calprotectin has the potential to be a functional biomarker and a new therapeutic target for APS thrombocytopenia.
Study context
- Population
- Patients with primary antiphospholipid syndrome (APS) and aPL-positive patients
- Exposure
- Primary APS and aPL-positive patients vs lupus, unprovoked venous thrombosis and healthy controls
- Primary APSn = 112
- aPL-positiven = 30
- Outcome
- Circulating plasma calprotectin levels (QUANTA Flash chemiluminescent assay)
Main finding
As reported in the abstract
Circulating calprotectin
- Calprotectin higher in primary APS and aPL-positive patients vs healthy controls
- Correlation with absolute neutrophil count (age- and sex-adjusted), r = 0.41, P < 0.001
- Correlation with CRP (age- and sex-adjusted), r = 0.34, P = 0.002
- Correlation with platelet count (age- and sex-adjusted), r = −0.24, P = 0.004
- Calprotectin provoked aPL-mediated thrombocytopenia via platelet surface toll-like receptor 4 and NLRP3-inflammasome activation, reducing platelet viability in a caspase-1-dependent manner
- Adjusted for age and sex
Observational data: associations, not effects.
Original publication
Calprotectin Impairs Platelet Survival in Patients With Primary Antiphospholipid Syndrome. Arthritis Rheumatol. Published 15 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →